How to access Zeposia from the UAE, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-24
An Emirati patient with relapsing multiple sclerosis (MS) or moderately-to-severely active ulcerative colitis (UC) may receive a prescription for Zeposia (ozanimod) from their treating neurologist or gastroenterologist. Zeposia is FDA-approved for both indications and is developed by Bristol Myers Squibb. It is an oral sphingosine-1-phosphate (S1P) receptor modulator. In the UAE, Zeposia is not routinely registered for outpatient dispensing across all pack sizes, and access is typically coordinated through the named-patient import pathway.
This guide explains the pathway, documentation your physician prepares, typical timing and how quotes work, and where Reserve Meds fits in.
Ask about Zeposia in UAE
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Zeposia is an S1P₁/S1P₅ receptor modulator that sequesters lymphocytes in lymphoid tissue, reducing their circulation to sites of inflammation. It is taken orally once daily. A 7-day titration pack is used at initiation (0.23 mg days 1-4, 0.46 mg days 5-7, 0.92 mg from day 8), reaching maintenance at 0.92 mg daily. The titration profile is designed to manage the first-dose bradycardia and heart-block signal characteristic of the S1P-modulator class.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Before starting, your physician will establish a baseline ECG, review cardiac history (recent MI, stroke, heart block, heart failure), confirm complete blood count including absolute lymphocyte count, baseline liver function tests, dermatology review, and an ophthalmologic assessment (macular oedema risk). Varicella zoster immunity is confirmed and live vaccines are avoided during therapy. Ongoing monitoring includes LFTs, lymphocyte count, and skin surveillance.
Is Zeposia legally importable into the UAE?
Yes, through the UAE Ministry of Health and Prevention (MoHAP) named-patient import framework, with parallel authority through the Department of Health (DoH) in Abu Dhabi and Dubai Health Authority (DHA) in Dubai depending on where the prescribing facility sits. The mechanism permits an Emirati-licensed physician to import a medicine not locally registered when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent registered alternative is suitable, (c) the physician accepts clinical responsibility, and (d) chain of custody is documented. S1P-modulator named-patient imports for MS and UC are a familiar category.
How the pathway works, step by step
- Consultation with your treating specialist. Confirmation of MS subtype or UC severity, prior therapy history, and clinical rationale for an S1P modulator.
- Baseline workup. ECG, cardiac review, CBC with lymphocyte count, LFTs, ophthalmology baseline, varicella serology, dermatology review.
- MoHAP named-patient application. The physician or hospital pharmacy files the application including clinical rationale, patient reference, titration plan, and chain-of-custody commitment.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure Zeposia from authorised distribution under DSCSA.
- Ambient shipment. Zeposia ships under controlled ambient conditions with chain-of-custody documentation.
- Arrival and first dose. The dispensing pharmacy releases the 7-day starter pack; first-dose cardiac monitoring is arranged per your physician's protocol.
What documentation your physician needs
- Clinical rationale letter confirming indication and Zeposia as the indicated therapy
- Verification of the UAE medical licence
- Baseline ECG report and cardiac review
- CBC with lymphocyte count and LFTs
- Varicella serology result
- Ophthalmology baseline
- Planned titration schedule and monitoring plan
Reserve Meds provides a physician documentation kit bundling templates MoHAP reviewers expect for S1P-modulator named-patient imports.
Typical costs and indicative timing
Medicine price: quote on request. You get a written quote for your case before you commit. International logistics, MoHAP documentation handling, and coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake.
We give you a written timeline estimate for your case before you commit. Monthly refills are generally faster once the pathway is established.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Reserve Meds's role
- Sourcing. Through our US-licensed pharmaceutical wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and MoHAP review.
- Logistics. Ambient-controlled shipment to your prescribing hospital pharmacy.
- Dedicated case lead. A named point of contact coordinating monthly refills.
What we do not do: we are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating physician.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP / DoH / DHA named-patient framework with appropriate documentation. See our trust and compliance page.
Why the titration pack? S1P-modulator therapy can cause first-dose bradycardia and transient conduction effects. The gradual titration is designed to manage this and is part of standard FDA-labelled initiation. Your physician will advise on first-dose observation.
Can I get live vaccines during therapy? Live vaccines are avoided during S1P-modulator therapy. Your physician will plan any vaccination updates before starting and address strategy during therapy and wash-out.
How does Zeposia compare with other S1P modulators? Zeposia, Ponvory, Mayzent, and older fingolimod are all S1P modulators; receptor-subtype selectivity, titration, and indication approvals differ. Your specialist selects based on indication, comorbidity profile, and tolerability considerations.
Will insurance cover this? Cash-pay is the default. Some UAE private insurers consider case by case; we supply documentation but do not process claims directly.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-24.
Abu Dhabi and Dubai
This guide covers the whole UAE, including Abu Dhabi and Dubai. At federal level, medicines are regulated by the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP). MOHAP also issues permits to import medicines for personal use. Hospitals, clinics and doctors are licensed by the health authority of their own emirate: the Department of Health Abu Dhabi (DoH) in Abu Dhabi, and the Dubai Health Authority (DHA) in Dubai.
In practice, the hospital that treats you follows the rules of its own emirate, so the paperwork is prepared for that hospital. Tell us which hospital or doctor is treating you, in Abu Dhabi, Dubai or another emirate, and we prepare the document pack for that route.
Sources: Department of Health Abu Dhabi; Dubai Health Authority, Health Regulation Sector; MOHAP, permit to import medicines for personal use; Simmons & Simmons, UAE pharmaceutical law and the Emirates Drug Establishment.
Frequently asked questions
How can I get Zeposia in the UAE if it is not approved or available there?
Reserve Meds coordinates US-sourced Zeposia for patients in the UAE through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for the UAE and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Zeposia in the UAE through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Zeposia. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in the UAE, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Zeposia in the UAE through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Zeposia to a patient in the UAE?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Zeposia to your treating physician or hospital pharmacy in the UAE, with appropriate handling for the product.
How long does it take, and what does Zeposia in the UAE cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Zeposia in the UAE?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.